

Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 BurrowsR@ebsi.com

Media Contact: Tracey Schmitt Vice President, Global Public Affairs and Corporate Responsibility 240-631-3394 SchmittT@ebsi.com

EMERGENT BIOSOLUTIONS TO RELEASE SECOND QUARTER 2015 FINANCIAL RESULTS AND CONDUCT A CONFERENCE CALL ON AUGUST 6, 2015

GAITHERSBURG, MD, July 23, 2015—Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, August 6, 2015 at 8:00 am (Eastern Time) to discuss the financial results for the second quarter of 2015, recent business developments, financial outlook for full year 2015, and revenue guidance for the third quarter of 2015.

This conference call can be accessed live by telephone or through Emergent's website:

Live Teleconference Information:

Dial in number: **(855) 766-6521** International dial in: (262) 912-6157 Passcode: **78708197** Live Webcast Information: Visit <u>www.emergentbiosolutions.com</u> and select the <u>"Investors</u>" section

Pre-registering for the live call will expedite access and minimize hold times. You will be issued a passcode to bypass the operator and connect directly. To pre-register for the call, visit the following website: <u>http://edge.media-server.com/m/p/gprwpcvd/lan/en</u>.</u>

A replay of the call can be accessed on Emergent's website <u>http://www.emergentbiosolutions.com</u> under "<u>Investors</u>."

About Emergent BioSolutions Inc.

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. We also develop and commercialize therapeutics and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com.

Follow us on twitter: <u>@emergentbiosolu</u>.